Reboxetine and cytochrome P450 – comparison with paroxetine treatment in humans

Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study

“…Nevertheless, we must also consider the possibility of drug interactions, as well as an increase in side effects, though these concerns are especially severe in the case of TCA, they will not be so in that of reboxetine, because its affinity for the different receptors responsible for the adverse effects of antidepressants is very low (Fleishaker, 2000;Wong, et al, 2000), and it does not inhibit or induce important CYP isoenzymes, reason why no clinically relevant drug interactions involving CYP2D6 are anticipated (Kuhn, et al, 2007).…”

“…In general, combination therapy should be considered an alternative to the switching strategy in partial responders, because it conserves the partial beneficial effects obtained, minimising the demoralising psychological effect of failure for the patient, avoids the appearance of withdrawal symptoms, permitting the use of lower doses of the antidepressants used and improves certain symptoms not well resolved by the first antidepressant and 'ameliorates' some of its adverse effects, as well as provides the possibility of obtaining a more rapid response than that obtained by the switching strategy (Sokolov and Joffe, 1995;Lam, et al, 2002). Nevertheless, we must also consider the possibility of drug interactions, as well as an increase in side effects, though these concerns are especially severe in the case of TCA, they will not be so in that of reboxetine, because its affinity for the different receptors responsible for the adverse effects of antidepressants is very low (Fleishaker, 2000;Wong, et al, 2000), and it does not inhibit or induce important CYP isoenzymes, reason why no clinically relevant drug interactions involving CYP2D6 are anticipated (Kuhn, et al, 2007).…”

Multiple drug interactions - induced serotonin syndrome: a case report

“…Although its serotonin reuptake inhibition is weak when administered in association to other SSRI, such as citalopram or fluoxetine, this effect could be enhanced (10). Reboxetine is also a weak inhibitor of the CYP2D6 and CYP3A4 isoenzymes (11), both of which participate in the metabolism of citalopram, producing a possible pharmacokinetic interaction.…”

Pharmacogenomics of Antidepressants

“…Kuhn et al, [82] studied the pharmacokinetics of reboxetine in relation to pharmacogenetics and the effects of reboxetine compared to paroxetine treatment on the CYP2D6 and CYP3A4 phenotype. Reboxetine serum concentrations showed no correlation with the CYP2D6 genotype and the CYP2D6 phenotype, whereas paroxetine concentrations showed some dependence on CYP2D6.…”